Detalles de la búsqueda
1.
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood
; 140(22): 2348-2357, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35921541
2.
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Hematol Oncol
; 42(1): e3216, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37772620
3.
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Hematol Oncol
; 42(1): e3249, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38287529
4.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Blood
; 137(25): 3507-3517, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33651883
5.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36632738
6.
Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study.
Hematol Oncol
; 41(3): 363-370, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36762406
7.
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Hematol Oncol
; 41(5): 877-883, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37392141
8.
Acquired hemophilia A and delta storage pool deficiency in a patient with indolent non-Hodgkin lymphoma.
Platelets
; 33(1): 168-170, 2022 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33426985
9.
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Br J Haematol
; 193(2): 325-338, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33605445
10.
FZD6 triggers Wnt-signalling driven by WNT10BIVS1 expression and highlights new targets in T-cell acute lymphoblastic leukemia.
Hematol Oncol
; 39(3): 364-379, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33497493
11.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Hematol Oncol
; 39(3): 326-335, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739461
12.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33378569
13.
CD34-Positive Blast Count and p53 Expression in Bone Marrow Biopsies of Patients with Low-Risk Myelodysplastic Syndromes: Potential Predictive Tools of Response to Erythropoietin Stimulating Agents.
Pathobiology
; 88(3): 242-250, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33588425
14.
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.
Br J Haematol
; 190(6): 901-908, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32712965
15.
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
Blood
; 138(25): 2727-2730, 2021 12 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34587233
16.
Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report.
Hematol Oncol
; 41(1): 201-204, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35849302
17.
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia.
Hematol Oncol
; 41(3): 567-570, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36190298
18.
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Am J Hematol
; 98(7): E157-E160, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37067157
19.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Am J Hematol
; 98(9): E237-E240, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382471
20.
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Am J Hematol
; 98(2): E24-E27, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36349541